MedTrace Logo

Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin

NCT00441363 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2016-05-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy alone.

Conditions

Interventions

DRUG

Bromocriptine Mesylate

0.8 mg tablet

Sponsors & Collaborators

  • VeroScience

    lead INDUSTRY

Principal Investigators

  • Richard E Scranton, MD · VeroScience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2006-02-28
Completion
2006-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441363 on ClinicalTrials.gov